

# Pharmacokinetics in Drug Development - an Integrated Approach



11 & 12 June 2012

Window Conference Venue, Islington London UK

*PK understanding to aid your drug development programmes*

The UK, like most developed countries, has an ageing population. In the 2001 population census, the average age was 39.0 years, an increase on 1971 when it was 34.1 years. In mid-2006 approximately one in five people in the UK were aged under 16 and one in six people were aged 65 or over. With advancing age comes increased medicine use, furthermore elderly patients are likely to be taking several concomitant medications. This greater drug usage makes them more at risk of suffering from adverse events as a result of drug drug interactions (DDIs). DDIs may be metabolic, transporter, physicochemical or dynamic in nature. In drug development, advances in *in vitro* science and modelling software have helped to screen out compounds that are most at risk of DDIs before they enter into man. The need to investigate DDIs in the clinic though has not disappeared. Several regulatory agencies have drug interaction guidances; in particular the FDA has recently released a draft guidance entitled 'Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling' that takes account of current thinking in the field. An understanding of the pharmacokinetic/pharmacodynamics of the compound, linked to the relevant regulatory guidances is required to deliver a safe and effective medicine that can be used by patients concomitantly with other remedies.

## What will participants gain?

- Understanding of the common PK terms and their importance
- Understanding of how PK data influences the clinical development Programme
- An understanding of the factors that contribute to variability in PK
- The role of PKPD modelling in drug development
- An appreciation of how regulatory guidances influence PK
- Increased confidence to discuss PK issues within their drug projects

## Comment from previous attendee:

"Very good, certainly useful, really made me see things from a different perspective rather than just as a formulator!"

[www.pharma-training-courses.com](http://www.pharma-training-courses.com)



## Course objectives:

To provide participants with an overview of the principles of Pharmacokinetics and Pharmacokinetic/Pharmacodynamic modelling and how together with regulatory guidances they can be used to effectively deliver drug development programmes.

## Who will benefit:

The course is intended for all professionals in the drug development arena especially those that work in or with clinical project teams (eg Regulatory Affairs specialists; Medical personnel; Project managers/leaders; Clinical research associates) who want to further their knowledge of the usefulness of PK in their projects.

Course will commence with registration at 8.30am, course proper at 9.30am and will finish at 5.00pm each day.

## Course Programme

### Day 1: Pharmacokinetic Principles

*What is PK and why is it important*

Absorption, distribution, metabolism and elimination

- Transporters
- Drug failures
- Therapeutic windows

*PK terminology*

- Clearance, volume of distribution etc. What they are and what is their Importance

*PK techniques*

- Non compartmental Analysis
- Compartmental modelling
- Population pharmacokinetics
- Regulatory environment
- Data interpretation

### Day 2: PK in Drug Development

*Pre-clinical/clinical interface*

- What PK data are available, how does this influence the Clinical PK strategy
- Biomarkers
- Implications for CTA-dose choice and dose escalation in first to man studies, adaptive dosing

*Variability in PK*

- Drug interactions; CYPs and transporter strategies and regulatory guidance;
- Types of interaction competitive vs mechanism based; implications for study design (restrictions healthy volunteers vs patients etc)
- Genetic polymorphisms
- Renal and hepatic impairment

*Biologics*

- Pharmacokinetics/Pharmacodynamics
- Study Design
- Regulatory environment

*Participants will need to bring along a scientific calculator*

There will also be several “learning in action” workshops during both days where participants will have the opportunity to apply knowledge gained during the lectures. An open forum session will be held where delegates can bring along their own issues for discussion.



## Venue

**Window Conference Venue** 13 Windsor Street, Islington London, N1 8QG  
convenient for central London, in a pleasant informal setting.

Course fee includes all course materials, refreshments, and lunch, accommodation is not included.

Accommodation and travel directions are available on our website

[www.pharma-training-courses.com](http://www.pharma-training-courses.com)

## Course Speaker: Dr Graham Blakey

Graham graduated with a BSc (Hons) degree in Pharmacy before undertaking various roles in hospital pharmacy. He gained an MSc in Clinical Pharmacology from the University of Glasgow. This experience developed Graham's interest in pharmacokinetics and lead to a PhD with Prof Malcolm Rowland at the University of Manchester. His thesis was entitled 'Tissue kinetics of a series of barbiturates'.

Graham spent 12 years with AstraZeneca Charnwood where he held several roles including Principal Scientist and Head of Clinical Pharmacokinetics. During this time he gained extensive experience in providing clinical pharmacology strategy including pharmacokinetic/pharmacodynamic input and analysis to all phases of clinical drug development. Graham has worked in many global project teams, as a clinical pharmacokineticist and project leader, in several therapeutic areas including: inflammation, cardiovascular and CNS. Output from these teams has supported drug development in Europe, Japan and North America.

Graham has a particular interest in the determination of clinically relevant drug interactions. Throughout his career he has pioneered the use of probe drugs (including the cocktail approach) as clinical markers of the activity of the Cytochrome P450 drug metabolising isoenzymes. His work in inflammation centred on rheumatoid arthritis and osteoarthritis and saw several novel compounds progress from pre-clinical to patient studies. Graham now works in consultancy providing clinical pharmacology and pharmacokinetic expertise.

We deliver a range of expert programmes in pharmaceutical development, quality assurance and regulatory topics, plus a range of industry awareness courses. We employ speakers/trainers with a high degree of expertise, completely up to date with industry trends.

*Please check our website for other courses added throughout the year.*

**PharmaTraining**

**BioCity**

**Pennyfoot Street**

**Nottingham NG1 1GF**

**Tel: ++44 (0)1159 124249**

**Fax: ++44 (0)20 7681 3582**

**Email: [info@pharma-training-courses.com](mailto:info@pharma-training-courses.com)**

## REGISTRATION FORM:

**Pharmacokinetics in Drug Development—an integrated approach - 11 & 12 June 2012**  
**London**

2 day course £1062.00 + VAT £232.40 (if applicable see VAT Notes) **Total £1294.40**  
*if booked and paid by 6 April 2012*

Full fee 2 day course £1180.00 + VAT £236.00 (if applicable see VAT Notes) **Total £1416.00**

Discount of 10% applies for booking 8 weeks in advance. Discount of 10% applies for booking more than 1 delegate. Discount of 10% applies for booking more than 1 course

**Maximum discount received is 15%**

## VAT NOTES:

**UK:** Under UK law all UK-based applications are subject to VAT at the prevailing rate however most UK VAT registered companies/organisations can reclaim this tax.

**EU:** With effect from 1 January 2011 applications from delegates whose companies are based in EU countries will not be subject to VAT **PROVIDED THAT** valid VAT ID details are provided at the time of booking, otherwise VAT will be charged.

**VAT ID No.** \_\_\_\_\_

**OTHER:** With effect from 1 January 2011 applications from delegates whose companies are based outside of the UK/EU will be outside the scope of VAT, ie no VAT is charged or payable.

Title (Mr/Mrs/Ms/Dr/Prof):

First Name:

Surname:

Company:

Job Title:

Address:

Post Code:

Country:

Tel:

Fax:

Email address:

Signature:

## Method of Payment:

☐ Cheque (Please make payable to "PharmaTraining Ltd")

☐ Bank transfer ☐ Credit/Debit Card (If paying by Credit Card please register online)

**Online Registration is available on our website:**  
**[www.pharma-training-courses.com](http://www.pharma-training-courses.com)**

Course fee includes all course material, refreshments and lunch, accommodation is not included

## Data Protection

PharmaTraining Ltd gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. If you have any queries or want to update any of the data that we hold then please contact us.

**Please send completed forms to →**

**PharmaTraining**  
BioCity Nottingham  
Pennyfoot Street  
Nottingham  
NG1 1GF  
UK

Tel: 0044 (0)115 9124249  
Fax: 0044 (0)20 7681 3582

[info@pharma-training-courses.com](mailto:info@pharma-training-courses.com)